Abintus Bio, Inc., headquartered in San Diego, is at the forefront of in vivo immune cell engineering. This innovative company focuses on developing genetic medicines that reprogram cells directly within the body, a process known as in vivo engineering. With a collective 90 years of experience in this field, Abintus aims to create potentially curative, off-the-shelf therapies that empower patients from within.

The company's primary market includes patients suffering from diseases such as lymphoma and solid tumors. Abintus Bio leverages its clinically proven Modular Delivery Platform (MDP) to develop these therapies. Their initial programs focus on the simultaneous engineering of a diverse range of active innate and adaptive immune cells, such as In Vivo CAR X, which has applications in treating various cancers.

Abintus Bio operates on a business model that involves significant research and development (R&D) to create its genetic medicines. The company generates revenue through partnerships, funding syndicates, and potentially future sales of its therapies. Initial funding has been secured from notable entities like Takeda Ventures and The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP).

The company is supported by a team of esteemed advisors, including Dr. Malcolm K. Brenner, a distinguished professor at Baylor College of Medicine with extensive expertise in cell and gene therapy. His research focuses on using gene transfer to enhance the immune response to human tumors, making him a valuable asset to Abintus Bio's mission.

In summary, Abintus Bio is a pioneering biotech company specializing in in vivo immune cell engineering to develop genetic medicines for cancer treatment. Their innovative approach and strong advisory team position them as a leader in this emerging field.

Keywords: in vivo, immune cell engineering, genetic medicines, cancer treatment, lymphoma, solid tumors, Modular Delivery Platform, biotech, San Diego, Takeda Ventures.